

**MONTHLY INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS AND
SHARES MAKING OF THE SHARE CAPITAL**
as per articles L233-8-II of « Code de Commerce » and
223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Date	Previous total number of shares making of the share capital	Previous total number of voting rights	Change explanation	New total number of shares making of the share	New total number of voting rights
31/01/2023	11.881.902	20 479 783	Fluctuation in the double voting rights	11.881.902	20 429 466

FOR MORE INFORMATION,
CONTACT:

VETOQUINOL

Investor Relations

Fanny Toillon

Tel.: +33 (0)3 84 62 59 88

relations.investisseurs@vetoquinol.com

ABOUT VETOQUINOL

Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.

As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At June 30th 2022, Vetoquinol employs 2621 people. Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

